{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:56:13Z","timestamp":1780372573030,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.maturitas.2014.01.001","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T16:16:32Z","timestamp":1389284192000},"page":"311-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Progestogens in postmenopausal hormone therapy and the risk of breast cancer"],"prefix":"10.1016","volume":"77","author":[{"given":"Irene","family":"Lambrinoudaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2014.01.001_bib0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.maturitas.2013.02.001","article-title":"Global Consensus Statement on menopausal hormone therapy","volume":"74","author":"de Villiers","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0010","doi-asserted-by":"crossref","unstructured":"The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257.","DOI":"10.1097\/gme.0b013e31824b970a"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/157488712799363253","article-title":"Vascular effects of estrogenic menopausal hormone therapy","volume":"7","author":"Reslan","year":"2012","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: an update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tips.2010.01.001","article-title":"Emerging role of estrogen in the control of cardiometabolic disease","volume":"31","author":"Cignarella","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0035","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/gme.0b013e3182843aad","article-title":"Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future","volume":"20","author":"Clarkson","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.maturitas.2008.11.011","article-title":"Pharmacological profile of progestins","volume":"61","author":"Sitruk-Ware","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0050","unstructured":"EMAS care online. Hormone therapy: what is it and practical issues."},{"key":"10.1016\/j.maturitas.2014.01.001_bib0055","unstructured":"statistics., NCIBc. http:\/\/seer.cancer.gov\/statfacts\/html\/breast.html accessed 20 December 2013."},{"key":"10.1016\/j.maturitas.2014.01.001_bib0060","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/gme.0b013e3181788d88","article-title":"Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer","volume":"15","author":"Vogel","year":"2008","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0065","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/djt207","article-title":"Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density","volume":"105","author":"Hou","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0070","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/djt043","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study","volume":"105","author":"Chlebowski","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ijc.24996","article-title":"Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland","volume":"127","author":"Lyytinen","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ijc.25314","article-title":"Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition","volume":"128","author":"Bakken","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.maturitas.2009.07.009","article-title":"Hormone therapy, mammographic density, and breast cancer risk","volume":"64","author":"Martin","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.maturitas.2005.08.012","article-title":"The effect of low dose hormone therapy on mammographic breast density","volume":"54","author":"Christodoulakos","year":"2006","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0095","doi-asserted-by":"crossref","unstructured":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047.","DOI":"10.1016\/S0140-6736(97)08233-0"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0100","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.gme.0000184221.63459.e1","article-title":"Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis","volume":"12","author":"Shah","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0105","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0110","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0115","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/AOG.0b013e31818fdde4","article-title":"Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer","volume":"113","author":"Jick","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0130","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/cncr.24101","article-title":"Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype","volume":"115","author":"Calle","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ijc.24738","article-title":"A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well","volume":"126","author":"Lyytinen","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1471-0528.2007.01520.x","article-title":"Hormone replacement therapy use and variations in the risk of breast cancer","volume":"115","author":"Opatrny","year":"2008","journal-title":"BJOG"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0145","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.fertnstert.2010.09.062","article-title":"Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women","volume":"95","author":"Murkes","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/AOG.0b013e31818e8cd6","article-title":"Breast cancer risk in postmenopausal women using estradiol-progestogen therapy","volume":"113","author":"Lyytinen","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0160","first-page":"673","article-title":"A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden)","volume":"14","author":"Jernstrom","year":"2003","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0165","first-page":"847","article-title":"Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States)","volume":"13","author":"Porch","year":"2002","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0170","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ijc.20389","article-title":"Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study","volume":"112","author":"Bakken","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0175","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3109\/09513590.2010.495437","article-title":"Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials","volume":"26","author":"Biglia","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2014.01.001_bib0185","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0800743","article-title":"The effects of tibolone in older postmenopausal women","volume":"359","author":"Cummings","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:59:36Z","timestamp":1759913976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512214000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0378512214000036"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.01.001","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progestogens in postmenopausal hormone therapy and the risk of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}